Aiforia Technologies

12/06/2026

📊 AI is transforming pathology, speeding up analysis, enhancing diagnostic accuracy, and addressing global healthcare resource shortages.

Featured in a recent special supplement of Talouselämä, our CEO, Jukka Tapaninen, shares how Aiforia is paving the way for the future of diagnostics. By automating time-consuming, repetitive tasks such as counting cells, measuring tumor size, or scanning for specific bacteria, AI frees up valuable time for pathologists.

Instead of spending tens of minutes on manual visual assessments, pathologists can focus on their core expertise and only verify the AI findings. "Digitalization and AI-based routine analytics offer concrete solutions for the everyday work of pathology laboratories,” says Jukka Tapaninen.

From Fimlab in Finland and the Paris hospital district (AP-HP) in France to the Mayo Clinic in the US, Aiforia's AI solutions are helping increase the speed, accuracy, and consistency of analyzing large, complex medical images.

Read the full article (in Finnish) to discover how Aiforia's solutions can help healthcare providers to overcome challenges and redefine the standards of cancer diagnostics ➡️ https://hubs.la/Q04lbf-t0

11/06/2026

Explore more of Aiforia's use cases at 2026, organized by the Society of Digital and Integrative Pathology (ESDIP) in Graz, Austria! 🇦🇹

📈 Poster P132: "The Impact of Artificial Intelligence Assistance on Interobserver Agreement in ER, PR, HER2, and Ki-67 Assessment"
🗣️ By Fadime Gul Salman (Turkiye) et al.

In this study, Salman et al. evaluated how the Aiforia® Breast Suite affects agreement among pathologists scoring breast cancer biomarkers in 296 cases. The use of AI increased diagnostic consistency and reduced scoring discrepancies for ER, PR, and HER2, notably decreasing complete disagreement for HER2 from 21% to 14%.

Check our interview with Dr. Serdar Balcı from Turkey Memorial Hospital to discover more about the study.

Stop by Aiforia's booth number 37 to learn more about real-life use cases and experience our AI solutions with a live demo 🖥️

11/06/2026

📢 NEWS: Aiforia has been selected to provide AI-assisted diagnostic solutions to a regional health service provider in Spain. The public tender was won by Palex, Aiforia’s strategic med tech partner in Spain.

Under the agreement, Aiforia will equip nine hospitals across the region with AI applications for breast and prostate cancer diagnostics. The solutions are intended to support pathologists in improving accuracy and efficiency in cancer detection and quantification.

“This agreement marks another important milestone in Aiforia’s expansion in Europe and strengthens our commitment to delivering innovative solutions and value to our customers. We are proud, together with Palex, to support this major healthcare region and its network of hospitals in enhancing cancer diagnostics and bringing advanced AI technologies into routine clinical practice,” said Jukka Tapaninen, CEO of Aiforia.

Read more: https://hubs.la/Q04k_HK80

09/06/2026

The 22nd European Congress on Digital Pathology (ECDP), organized by the European Society of Digital and Integrative Pathology (ESDIP), starts already next week in Graz, Austria! 🇦🇹

Explore one of Aiforia's use cases and join the following abstract presentation at 2026:

📊 "A Novel Prediction tool (AIFORIA) for Classifying Spindle Cell Lesion subtypes using Deep Learning on H&E Sections" by Dr. Kristijan Skok (Austria)
🗓️ June 19 at 14:50 CEST
📍 Session: “Machine Learning and Algorithm Development II"

In this proof-of-concept study, Skok et al. evaluated the performance of two AI models developed with Aiforia® Create, using standard CNNs and Aiforia's proprietary Foundation Engine, to classify complex spindle cell lesion subtypes from routine H&E slides via a weakly supervised approach. Key highlights from the study:

1. The standard CNN-based AI model showed strong sensitivity for solitary fibrous tumors (SFT) but struggled with class imbalance.
2. The AI model built on Foundation Engine provided a more balanced predictive approach, achieving an overall concordance of 64.9% while maintaining solid detection rates for Synovial Sarcoma (66.2% recall).
3. Accurately identifying MPNST cases remains a complex challenge across all tested architectures, highlighting the need for further dataset expansion and targeted model optimization to enhance clinical applicability.

Check the video to hear Dr. Kristijan Skok and Prof. Dr. Bernadette Liegl-Atzwanger discuss their research and the use of AI in clinical pathology: https://hubs.la/Q04kGNq50

Would you like to discover more about Aiforia's portfolio of AI solutions and real-life use cases? Visit our experts at booth number 37 to learn more. 🖥️

Explore one of Aiforia's use cases and join the following abstract ...

05/06/2026

Aiforia's team is heading to Padua, Italy, next week to attend the Diagnostic Histopathology of Skin Disease 🇮🇹 Have a chance to connect with Jukka Tapaninen, Fabio Papadia, Emilia Lönnberg, and learn more about:

◽️ Aiforia® Create - the most versatile tool for developing deep learning AI models for image analysis in digital pathology.

◽️ Aiforia® Foundation Engine Technology, the next-generation AI technology platform, and how using foundation models can help reduce the annotation workload, speeding up the AI training.

◽️ Aiforia® Clinical Suites and how clinical AI solutions can enhance efficiency, consistency, and diagnostic accuracy in pathology workflows. Clinical Suites consist of a wide range of CE-IVD marked AI models with an optimized interactive user interface.

Visit our booth to see Aiforia's AI solutions in action. Get in touch to arrange a meeting during the event or discover more already now ➡️ https://hubs.la/Q04kfg4R0

04/06/2026

We look forward to the upcoming 22nd European Congress on Digital Pathology (ECDP) organized by the Society of Digital and Integrative Pathology - ESDIP in Graz, Austria! 🇦🇹

Stop by booth number 37, meet our experts, Panu Kauppila, Darshan Kumar, David Guet, Fabio Papadia, Julien Courtial, Andreea Luchian, and Emilia Lönnberg, and:

▶️ Experience firsthand Aiforia’s broadest collection of AI models designed to support precision and efficiency in pathology workflows, including our most recent CE-IVD marked solutions for gastric cancer (Aiforia® Gastric Cancer) and the next generation of clinical AI solution for prostate cancer diagnostics - Aiforia® Prostate Cancer Biopsy.

▶️ Explore Aiforia® Create, Aiforia’s versatile tool for developing AI models for image analysis in digital pathology, and see how it allows pathologists and other domain experts to build and evaluate their own deep learning AI models.

▶️ Discover more about Aiforia Foundation Engine Technology and learn how pre-trained foundation models can reduce AI model development timelines, improve robustness, and, when combined with pathologists’ task-specific annotations, provide even greater precision in clinical workflows.

See more of Aiforia’s highlights at or get in touch with us in advance to secure a time for an AI demo on-site: https://hubs.la/Q04k3yN30. We are excited to see you!

01/06/2026

🇫🇷 In France on June 11-12

Aiforia's Julien Courtial and David Guet will be at the 49th National Conference on Pathology (Assises de Pathologie) next week in Le Touquet, France. Visit us at booth number 18 to discover how Aiforia's powerful deep learning AI and cloud-based solutions strive to increase the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology.

Would like to learn more about Aiforia’s solutions for AI-assisted image analysis and see a live demo? Get in touch ➡️ https://hubs.la/Q04jvYPW0

25/05/2026

Choosing a digital pathology platform is a long-term investment with huge strategic implications. Where should you start your search? 🔎 🖥️

Recent landscape analysis by Winter et al. (2026) breaks down the evaluation criteria across 14 selected digital pathology platforms. Our latest content piece explores the study's practical selection criteria and recommendations for clinical laboratories, and is supplemented by Aiforia's three takes on the topic. 💡

Read the full blog post to catch the 6+3 core parameters for digital pathology platform comparison: https://hubs.la/Q04hMFmh0

22/05/2026

Speeding up image analysis time from weeks to minutes. ⏱️ That's how AI is transforming preclinical synucleinopathy research.

Traditional characterization of histological samples in neurodegenerative disease research is labor-intensive and time-consuming. To tackle this bottleneck, a team of researchers at KU Leuven developed an innovative AI-powered pipeline for high-throughput, unbiased analysis of mouse brain tissues.

The study introduces five specialized AI models, trained and deployed using Aiforia® Create, capable of autonomously identifying brain regions and detecting critical markers of:

🧠 Neurodegeneration
🧠 Neuroinflammation
🧠 Alpha-synuclein protein aggregation

The results? ➡️ Accurate, region-specific insights at cell-level resolution through automated quantification, reducing analysis time from weeks down to minutes.

Read the full open-access study here: https://hubs.la/Q04hBqyT0

Preclinical animal models are indispensable for uncovering disease mechanisms and developing novel therapeutic interventions in synucleinopathies. Key readouts including neuronal cell death, neuroinflammation and alpha-synuclein protein aggregation, are routinely assessed by histological methods. Ho...

20/05/2026

🇫🇮 The International Academy of Pathology (IAP) Finland Spring Meeting starts already tomorrow in Helsinki, Finland.

Have a chance to connect with our Account Executive, Mikael Jääskeläinen, and learn more about how Aiforia® Clinical Suites and other AI solutions can enhance efficiency, consistency, and diagnostic accuracy in pathology workflows.

Get in touch to arrange a meeting and see a live AI demo during the event, or discover more already now ➡️ https://hubs.la/Q04hgSql0